Abbott Laboratories (ABT)

NYSE · Healthcare

Latest Move · 2026-02-02

+4.49%
Rebounds on Exact Sciences acquisition optimism and positive clinical data

ABT Stock Movement Summary Abbott Laboratories (ABT) rebounded following announcements regarding the Exact Sciences acquisition and positive clinical data. Key Facts: - Abbott announced a $21 billion acquisition of Exact Sciences to expand into cancer diagnostics, addressing portfolio challenges in its Nutrition segment. - The company is increasing focus on diabetes and cardiovascular products as part of a strategic repositioning. - Abbott released two-year data from its SUMMIT-MAC trial supporting the safety and effectiveness of its Tendyne transcatheter mitral valve replacement system. - Q4 results fell below Wall Street expectations due to weakness in the Nutrition segment. - Freedom Capital Markets upgraded ABT to Buy from Hold, citing long-term prospects from the Exact Sciences integration expected in Q2 2026. - Multiple analysts adjusted price targets following earnings, with Leerink Partners lowering its target to $119 and Wells Fargo lowering its target to $122.

Read full analysis

Frequently Asked Questions

Why did Abbott Laboratories stock move today?

ABT Stock Movement Summary Abbott Laboratories (ABT) rebounded following announcements regarding the Exact Sciences acquisition and positive clinical data. Key Facts: - Abbott announced a $21 billion acquisition of Exact Sciences to expand into cancer diagnostics, addressing portfolio challenges in its Nutrition segment. - The company is increasing focus on diabetes and cardiovascular products as part of a strategic repositioning. - Abbott released two-year data from its SUMMIT-MAC trial supporting the safety and effectiveness of its Tendyne transcatheter mitral valve replacement system. - Q4 results fell below Wall Street expectations due to weakness in the Nutrition segment. - Freedom Capital Markets upgraded ABT to Buy from Hold, citing long-term prospects from the Exact Sciences integration expected in Q2 2026. - Multiple analysts adjusted price targets following earnings, with Leerink Partners lowering its target to $119 and Wells Fargo lowering its target to $122.

What does Abbott Laboratories do?

Abbott Laboratories (ABT) is a publicly traded company in the Healthcare sector.

Healthcare Stocks

AI-generated analysis · Not financial advice · Always do your own research
Disclaimer & Terms · Privacy Policy